See All Slides - tctmd.com

Slides

Presentation TCT 2012

Dynamic Obstruction: Mechanisms and Implications for Treatment

Presenter: Carey Kimmelstiel

October 25, 2012

Presentation TCT 2012

Step-by-Step Case: Percutaneous Closure of Mitral Paravalvular Leak: Anterograde Approach

Presenter: Charanjit Rihal

October 25, 2012

Presentation TCT 2012

What Is FFR, and How Is It Different from Other Indices?

Presenter: William Fearon

October 25, 2012

Presentation TCT 2012

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

Presenter: Suhas Lele

October 25, 2012

Presentation TCT 2012

The European TAVR “Test Track”: After 5 Years, Have TAVR Use Patterns Drifted Out of Control?

Presenter: Nicolo Piazza

October 25, 2012

Presentation TCT 2012

For: The Transaortic Approach Has Clear Benefits Over the Transapical Approach!

Presenter: Vinayak Bapat

October 25, 2012

Presentation TCT 2012

Case 1: OCT Case

Presenter: Jingbo Hou

October 25, 2012

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

Presentation TCT 2012

Genetic Testing for 9p21: The Case for Health Care Insurance Reimbursement

Presenter: H. Robert Superko

October 25, 2012

Presentation TCT 2012

Managing a Peripheral Coronary Perforation

Presenter: Koen Teeuwen

October 25, 2012

Advertisement

Slides

Dynamic Obstruction: Mechanisms and Implications for Treatment

Step-by-Step Case: Percutaneous Closure of Mitral Paravalvular Leak: Anterograde Approach

What Is FFR, and How Is It Different from Other Indices?

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

The European TAVR “Test Track”: After 5 Years, Have TAVR Use Patterns Drifted Out of Control?

For: The Transaortic Approach Has Clear Benefits Over the Transapical Approach!

Case 1: OCT Case

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Genetic Testing for 9p21: The Case for Health Care Insurance Reimbursement

Managing a Peripheral Coronary Perforation

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content